The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealings

18 Jun 2019 14:03

RNS Number : 6511C
Diurnal Group PLC
18 June 2019
 

18 June 2019

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Director Dealings

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following subscriptions for shares by Directors or persons closely associated with them in its recent Placing on the same terms as other investors, as disclosed in the circular issued on 28 May 2019:

 

Martin Whitaker, Chief Executive Officer, subscribed for 19,230 ordinary shares of 5 pence each in Diurnal Group plc ("Ordinary Shares") at a price of 26 pence per Ordinary Share. Following the transaction Martin Whitaker has a total interest of 69,959 Ordinary Shares, representing 0.08% of the total voting rights in the Company.

 

Richard Bungay, Chief Financial Officer, subscribed for 19,230 Ordinary Shares at a price of 26 pence per Ordinary Share. Following the transaction Richard Bungay has a total interest of 21,452 Ordinary Shares, representing 0.02% of the total voting rights in the Company.

 

Peter Allen, Chairman, subscribed for 84,722 Ordinary Shares at a price of 26 pence per Ordinary Share. Following the transaction Peter Allen has a total interest of 169,444 Ordinary Shares, representing 0.20% of the total voting rights in the Company.

 

John Goddard, Non-executive Director, subscribed for 38,461 Ordinary Shares at a price of 26 pence per Ordinary Share. Following the transaction John Goddard has a total interest of 103,476 Ordinary Shares, representing 0.12% of the total voting rights.

 

Alan Raymond, Non-executive Director, and his wife, Lynne Raymond, subscribed respectively for 19,231 and 19,230 Ordinary Shares at a price of 26 pence per Ordinary Share. Following the transaction Alan Raymond and his wife have a total interest of 67,349 Ordinary Shares, representing 0.08% of the total voting rights in the Company. 39,119 Ordinary Shares are held by Alan Raymond and 28,330 Ordinary Shares are held by his wife.

 

Capitalised terms used but not otherwise defined in this announcement bear the meaning ascribed to them in the circular issued by the Company on 28 May 2019.

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Panmure Gordon (UK) Limited (NOMAD and Joint Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

Corporate Broking: James Stearns

Cantor Fitzgerald Europe (Joint Broker)

+44 (0)20 7894 7000

Corporate Finance: Philip Davies, William Goode, Michael Boot

Healthcare Equity Sales: Andrew Keith

FTI Consulting (Investor Relations)

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

 

Notes to Editors

 

About Diurnal Group plc

 

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Martin Whitaker

Richard Bungay

Peter Allen

John Goddard

Alan Raymond

Lynne Raymond

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

Chief Financial Officer

Chairman

Non-Executive Director

Non-Executive Director

Wife of Non-Executive Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Subscription for shares

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

26p

19,230

26p

19,230

26p

84,722

26p

38,461

26p

19,231

26p

19,230

d)

 

Aggregated information

- Aggregated volume

- 200,104

- Price

- £52,028.08

e)

 

Date of the transaction

 

18 June 2019

f)

 

Place of the transaction

 

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHLLFIVRLITLIA
Date   Source Headline
6th Mar 202011:22 amRNSProposed Placing
5th Mar 20204:41 pmRNSDirectorate Change
28th Feb 20207:30 amEQSHardman & Co Research: Diurnal (DNL): . and more to come (news flow)
25th Feb 20203:06 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 202011:00 amRNSPrice Monitoring Extension
17th Feb 20201:46 pmRNSHolding(s) in Company
13th Feb 20207:00 amRNSUS FDA Accepts NDA Application for Alkindi
11th Feb 20207:00 amRNSInterim Results
20th Jan 20207:00 amRNSBusiness and trading update
13th Jan 20207:00 amRNSHolding(s) in Company
13th Jan 20207:00 amRNSNotice of Interim Results
10th Jan 20203:45 pmRNSDirector Dealings and Issue of Equity
10th Jan 20203:44 pmRNSIssue of Long-Term Incentive Plan awards
16th Dec 201911:46 amRNSDirector Dealings
16th Dec 20197:00 amRNSChronocort MAA Submitted in Europe
2nd Dec 20192:28 pmRNSShare Option Exercise and Issue of Equity
2nd Dec 20197:01 amRNSHolding(s) in Company
2nd Dec 20197:00 amRNSAlkindi New Drug Application Submitted to US FDA
26th Nov 201910:42 amRNSDirector Dealings and Issue of Equity
26th Nov 20197:15 amEQSHardman & Co Research: Diurnal (DNL): Successful DITEST Phase I trial outcome
21st Nov 20191:08 pmRNSResults of Annual General Meeting
21st Nov 20197:00 amRNSAGM Statement
20th Nov 20197:00 amRNSSuccessful outcome of testosterone clinical study
8th Nov 20197:00 amRNSVesting of LTIP awards
5th Nov 20197:30 amEQSHardman & Co Research: Diurnal (DNL): Approaching a number of near-term milestones
21st Oct 20196:23 pmRNSIssue of Equity
21st Oct 20191:09 pmRNSDirector Dealings
8th Oct 201911:26 amRNSPosting of Annual Report and AGM Notice
24th Sep 20197:00 amRNSResults for the year ended 30 June 2019
7th Aug 201911:04 amRNSDirector Dealings
5th Aug 201912:27 pmRNSDirector/PDMR Shareholding
26th Jul 20194:32 pmRNSHolding(s) in Company
8th Jul 20192:07 pmRNSDirector Dealings and Issue of Equity
3rd Jul 20197:00 amRNSMarket Authorisation Application in Australia
26th Jun 20193:57 pmRNSHolding(s) in Company
24th Jun 20199:39 amRNSDirector Dealings
21st Jun 20193:40 pmRNSHolding(s) in Company
21st Jun 20193:35 pmRNSHolding(s) in Company - Replacement
21st Jun 201910:18 amRNSChange of Auditor
19th Jun 20194:08 pmRNSHolding(s) in Company
18th Jun 20195:30 pmRNSHolding(s) in Company
18th Jun 20192:03 pmRNSDirector Dealings
17th Jun 201912:05 pmRNSDirector Dealings
14th Jun 201912:39 pmRNSResult of General Meeting and Issue of Equity
14th Jun 20197:00 amRNSResult of Open Offer
28th May 20197:00 amRNSPlacing, Open Offer and Notice of General Meeting
9th May 20197:00 amRNSIntent to Submit for MAA tendered to the EMA
2nd May 20193:29 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.